Mp72-06 importance of Primary Care Leadership Involvement: Recruitment Lessons From an Office-Based Urinary Incontinence Intervention

Abstract

Overall, of 139 patients who met our criteria, 29% received novel secondary hormone therapy. Compliance with NCCN Category 1 recommendations in terms of novel secondary hormone therapy was 68% overall, including 62% for mCSPC patients, 83% for M0 CRPC patients, and 70% for M1 CRPC. Compliance with Category 2A recommendations for adding novel hormone therapy was 16% overall. When we examined the compliance for individual practitioners, the compliance for the 5 highest-volume urologists ranged from 26-50% overall and 45-100% for Category 1 recommendations.CONCLUSIONS: Our findings demonstrate relatively low compliance with Category 1 and 2A recommendations for adding novel secondary hormone therapy in patients with advanced prostate cancer. There is an opportunity to immediately optimize treatment for these patients and future patients with quality improvement initiatives.